Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 31, 2024

Safety and Efficacy of Inebilizumab for the Treatment of NMOSD

The Lancet Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
Lancet Neurol 2024 Jun 01;23(6)588-602, BAC Cree, HJ Kim, BG Weinshenker, SJ Pittock, DM Wingerchuk, K Fujihara, F Paul, GR Cutter, R Marignier, AJ Green, O Aktas, HP Hartung, D She, W Rees, M Smith, D Cimbora, E Katz, JL Bennett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading